Avinger (AVGR)
(Delayed Data from NSDQ)
$1.29 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:51 PM ET
After-Market: $1.26 -0.03 (-2.33%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.29 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:51 PM ET
After-Market: $1.26 -0.03 (-2.33%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum B VGM
Zacks News
The Cooper Companies (COO) Beats Earnings Estimates in Q1
by Zacks Equity Research
The Cooper Companies Inc.(COO) reported adjusted earnings of $1.93 in first-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 7 cents and improving 5.5% on a year-over-year basis.
NxStage Medical: NxGen Hemodialysis System Now CE Marked
by Zacks Equity Research
NxStage Medical, Inc. (NXTM) recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis.
5 Stocks with Rising P/E to Enjoy Stellar Gains
by Zacks Equity Research
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Inogen (INGN) Tops Earnings & Revenues in Q4; View Upbeat
by Zacks Equity Research
Inogen Inc. (INGN) reported fourth-quarter 2016 earnings of 25 cents per share, which surpassed both the Zacks Consensus Estimate by 15 cents and the year-ago figure by 11 cents.
Varian (VAR): Calypso Tumor Tracking System Now in Brazil
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR), recently announced that Moinhos de Vento Hospital has become the first cancer treatment center in Brazil with Varian's flagship product Calypso, a tumor tracking system for cancer treatment.
Integer (ITGR) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Integer Holdings (ITGR) reported adjusted earnings of 87 cents per share in the fourth quarter of 2016, lower than the year-ago quarter figure of 92 cents.
Allscripts Launches Clinical Pathways for Cancer Treatment
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX) recently announced the launch of Clinical Pathways program for the treatment of cancer.
Patterson Companies (PDCO) Earnings Beat Estimates in Q3
by Zacks Equity Research
Patterson Companies Inc. (PDCO) reported third-quarter fiscal 2017 adjusted earnings of 58 cents per share from continuing operations, which came higher than the Zacks Consensus Estimate of 57 cents.
Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.
Inovalon (INOV) Q4 Earnings In Line, Revenue Beat Estimates
by Zacks Equity Research
Inovalon Holdings, Inc. (INOV) reported fourth-quarter 2016 adjusted earnings of 2 cents per share, which came in line with the Zacks Consensus Estimate.
Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter
by Zacks Equity Research
Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.
Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) reported adjusted loss of 6 cents per share in the fourth quarter of 2016, narrower than loss of 8 cents reported in the year-ago quarter and the Zacks Consensus Estimate of a loss of 11 cents.
DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles
by Zacks Equity Research
DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.
Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.
DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4
by Zacks Equity Research
DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.
CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4
by Zacks Equity Research
CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.
Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny
Varian (VAR) Eclipse Software Named Category Leader by KLAS
by Zacks Equity Research
Varian Medical Systems (VAR) recently announced that its Eclipse treatment planning software has been named 2017 Category Leader for Oncology Treatment Planning by KLAS.
Becton, Dickinson Launches BD Resolve Early Access Program
by Zacks Equity Research
Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.
New Strong Buy Stocks for February 14th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Cerner (CERN) Q4 Earnings Meet, Revenues Miss Estimates
by Zacks Equity Research
Cerner Corp(CERN) reported adjusted fourth-quarter 2016 earnings of 57 cents per share, in line with the Zacks Consensus Estimate.
New Strong Buy Stocks for February 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.